CE-Ventures, the corporate venture capital platform of Crescent Enterprises, has announced that its portfolio company CrossBridge Bio has signed a definitive agreement to be acquired by Eli Lilly and Company. The transaction gives the U.S. drugmaker a cancer therapeutics developer focused on precision-targeted treatments, while also delivering an exit for one of CE-Ventures’ early biotechnology bets. The announcement, made on April 14, 2026, positions the deal as a notable development for both the startup and the UAE-based investor’s healthcare portfolio.
Deal Terms
Under the terms disclosed by the companies, CrossBridge Bio shareholders could receive as much as $300 million in cash. The consideration includes an upfront payment and an additional payment tied to the achievement of a specified development milestone, indicating that part of the value remains dependent on future progress. While further financial details were not released, the structure reflects the continued market preference for milestone-based biotechnology acquisitions.
CrossBridge Bio’s Growth Path
CrossBridge Bio was founded in Houston in 2023 and has been building a platform centered on next-generation cancer therapies designed to improve how drugs are delivered to tumour cells. CE-Ventures co-led the company’s USD 10 million initial financing round in November 2024, helping support the business during an early and formative stage of development. Since then, the company has moved from platform validation toward clinical preparation, culminating in the agreement with Lilly less than three years after its launch.
Focus on Dual-Payload ADC Technology
At the center of the acquisition is CrossBridge Bio’s work in dual-payload antibody-drug conjugates, or ADCs, which are engineered to carry two therapeutic agents directly to cancer cells. The approach is intended to improve anti-cancer activity while also addressing some of the resistance issues that can limit the performance of existing treatments. Its lead programme, CBB-120, targets TROP-2, a glycoprotein found on the surface of certain cancer cells, and the company has said it expects to file an Investigational New Drug application for the candidate in 2026.
Strategic Significance for CE-Ventures
For CE-Ventures, the transaction serves as validation of its strategy of backing biotechnology companies developing first- and best-in-class therapies. Tushar Singhvi, Deputy CEO and Head of Investments at Crescent Enterprises, said the investor was proud to have supported CrossBridge Bio from an early stage and described Lilly as well placed to take the science further for patients. Damir Illich, Manager of Life Sciences at CE-Ventures and a board director at CrossBridge Bio, added that the company stood out early as a leader in dual-payload ADC development and said the new owner offers a strong path for continued advancement.
CrossBridge Bio’s Perspective and Investor Base
CrossBridge Bio management also framed the deal as the result of rapid progress enabled by early investor support and scientific differentiation. Chief executive and co-founder Dr. Michael Torres said CE-Ventures backed the company’s vision for next-generation ADCs at a formative point, helping the business move from concept to a platform capable of attracting a major pharmaceutical buyer. In addition to CE-Ventures, the startup has been supported by the Texas Medical Center Venture Fund, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and non-dilutive funding from CPRIT.
Broader Context
The acquisition also highlights the increasingly international nature of biotech venture investing, with a UAE-based corporate venture platform helping fund a Houston startup later acquired by a U.S. pharmaceutical group. CE-Ventures invests across consumer, deep-tech, and biotech sectors, while its parent, Crescent Enterprises, operates a broader multinational portfolio spanning logistics, food and beverages, healthcare, life sciences, aviation, private equity, and incubation activities. Against that backdrop, the CrossBridge Bio transaction stands out as a concrete example of how strategic venture capital can bridge early scientific innovation and large-scale pharmaceutical development.
If completed, the deal would give Eli Lilly access to a promising oncology platform at a time when targeted cancer therapies remain a major focus of pharmaceutical investment. For CrossBridge Bio, the agreement marks a swift transition from startup formation to acquisition, underscoring the commercial interest in differentiated ADC technologies. For CE-Ventures, it represents a milestone exit that strengthens its case for continued evidence-led investment in emerging life sciences companies.